Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Bridging the gap between histopathology and molecular pathology
From cancer research to diagnostic solutions
The blood test market worldwide is today around $75-80 billion
The combination will support clients in getting their end-to-end discovery and development programs delivered.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
The facility has been set up to manufacture tuberculosis testing cartridges
Proposed combination enhances Pfizer’s position as a leading company in oncology
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Subscribe To Our Newsletter & Stay Updated
